[Clinical trial of the effects of isodibut on several indicators of microcirculation in combined therapy of patients with diabetes mellitus]

Klin Med (Mosk). 1996;74(3):56-8.
[Article in Russian]

Abstract

The authors have tried a new drug isodibut, aldoreductase inhibitor, of Russian produce in 53 patients with diabetes mellitus. A course of isodibut++ has improved blood coagulation and fibrinolysis, microcirculatory blood flow, normalized muscular blood flow as indicated by electrocoagulation, conjunctival biomicroscopy, radionuclide tracing. The drug is recommended for treatment and prevention of diabetic angiopathy.

Publication types

  • Clinical Trial
  • Comparative Study
  • English Abstract

MeSH terms

  • Adult
  • Aged
  • Aldehyde Reductase / antagonists & inhibitors*
  • Blood Coagulation / drug effects
  • Conjunctiva / blood supply
  • Diabetes Mellitus / drug therapy*
  • Diabetes Mellitus / physiopathology
  • Diabetes Mellitus, Type 1 / drug therapy
  • Diabetes Mellitus, Type 1 / physiopathology
  • Diabetes Mellitus, Type 2 / drug therapy
  • Diabetes Mellitus, Type 2 / physiopathology
  • Diabetic Angiopathies / prevention & control*
  • Enzyme Inhibitors / administration & dosage
  • Enzyme Inhibitors / pharmacology
  • Enzyme Inhibitors / therapeutic use*
  • Female
  • Humans
  • Hypoglycemic Agents / administration & dosage
  • Hypoglycemic Agents / pharmacology
  • Hypoglycemic Agents / therapeutic use*
  • Isoquinolines / administration & dosage
  • Isoquinolines / pharmacology
  • Isoquinolines / therapeutic use*
  • Male
  • Microcirculation / drug effects*
  • Middle Aged
  • Muscles / blood supply

Substances

  • Enzyme Inhibitors
  • Hypoglycemic Agents
  • Isoquinolines
  • isodibut
  • Aldehyde Reductase